MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjögren's syndrome

OBJECTIVE: To establish an easy and practical assay for identifying systemic interferon (IFN) type I bioactivity in patients with primary Sjögren's syndrome (pSS). The IFN type I signature is present in over half of the pSS patients and identifies a subgroup with a higher disease activity. This...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Maria, Naomi I, Brkic, Zana, Waris, Matti, van Helden-Meeuwsen, Cornelia G, Heezen, Kim, van de Merwe, Joop P, van Daele, Paul L, Dalm, Virgil A S H, Drexhage, Hemmo A, Versnel, Marjan A
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2014
Pynciau:
Clinical and Epidemiological Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4033122/
https://ncbi.nlm.nih.gov/pubmed/23831963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2012-202552
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg